Dr Stephen Young

Stephen joined Sygnature in January 2016 from Hitgen where he was Vice President of Business Development, establishing several early research collaborations for this Chinese CRO start-up. Prior to Hitgen he held business development positions at Pharmacia, Novabiochem and Protherics. He is a highly-experienced Medicinal Chemist and has worked in a broad range of therapeutic areas within small and large discovery organisations including MSD, Proteus, Tularik, Amgen and Vertex, where he led the Discovery Chemistry department in the UK.

Stephen holds a BSc (Hons.) in Chemistry and a PhD in Medicinal Chemistry from the University of Nottingham. He also undertook post-doctoral research at the University of Edinburgh in the area of peptide synthesis methodology.